Company news

Cellectar Biosciences, Inc. news in 2025

Cellectar Biosciences, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies

December 16, 2025

Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 13, 2025

Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025

November 6, 2025

Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma

October 27, 2025

Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research

October 14, 2025

Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million

October 7, 2025

Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM)

October 6, 2025

Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer

September 30, 2025

Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer (TNBC)

September 24, 2025

Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225

September 11, 2025

Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit

September 9, 2025

Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September

September 5, 2025

Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research

September 3, 2025

Cellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer

August 27, 2025

Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

August 14, 2025

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025

August 7, 2025

Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option

July 2, 2025

Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering

July 1, 2025

Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement

June 26, 2025

Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)

June 24, 2025

Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split

June 18, 2025

Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma

June 11, 2025

Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules

June 5, 2025

Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)

June 4, 2025

Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update

May 13, 2025

Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025

May 7, 2025

Cellectar Announces Plan to Explore Strategic Alternatives

April 30, 2025

Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update

March 13, 2025

Cellectar Biosciences to Present at the 37th Annual Roth Conference

March 11, 2025

Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025

March 5, 2025

Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

February 4, 2025

Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare Conference

January 11, 2025

Calls in 2025

Decks in 2025